GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

4 weeks ago

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 ( received in August 2024 ) upon first sale of Ipsen's Iqirvo® ( elafibranor ) in the U.S. for the treatment of Primary Biliary Cholangitis ( PBC )

Ticker	Sentiment	Impact
GNFT	Neutral	19 %